EE158 Economic Evaluation of Duvelisib Versus Ofatumumab in Relapsed/Refractory CLL/SLL in Japan

Abstract

Authors

K Shimizu K Moriwaki K Morimoto K Shimozuma

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×